Get the Stockscreener App
2.17
2.84%
0.06
After Hours:
2.38
0.21
+9.68%
Ernexa Therapeutics Inc stock is traded at $2.17, with a volume of 5,966.
It is up +2.84% in the last 24 hours and down -46.81% over the past month.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
See More
Previous Close:
$2.11
Open:
$2.1
24h Volume:
5,966
Relative Volume:
0.05
Market Cap:
$2.53M
Revenue:
$1,000
Net Income/Loss:
$-11.39M
P/E Ratio:
-0.0706
EPS:
-30.7182
Net Cash Flow:
$-7.26M
1W Performance:
-12.85%
1M Performance:
-46.81%
6M Performance:
-54.10%
1Y Performance:
-93.42%
1-Day Range:
$2.0495
$2.2299
1-Week Range:
$2.0127
$2.49
52-Week Range:
$2.0127
$71.50
Ernexa Therapeutics Inc Stock (ERNA) Company Profile
Name
Ernexa Therapeutics Inc
Sector
Industry
Phone
(617) 798-6700
Address
1035 CAMBRIDGE STREET, CAMBRIDGE
Compare ERNA vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERNA
Ernexa Therapeutics Inc
|
2.17 | 2.53M | 1,000 | -11.39M | -7.26M | -30.72 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ernexa Therapeutics Inc Stock (ERNA) Latest News
Price to earnings forward of Ernexa Therapeutics Inc. – NASDAQ:ERNAW - TradingView
Enterprise value to EBIT forward of Ernexa Therapeutics Inc. – NASDAQ:ERNAW - TradingView
Enterprise value to revenue forward of Ernexa Therapeutics Inc. – NASDAQ:ERNAW - TradingView
Director takes 2026 cash pay in options at Ernexa (ERNA) - Stock Titan
Ernexa Therapeutics (ERNA) director granted options in place of cash fees - Stock Titan
Ernexa Therapeutics (ERNA) grants director 5,944-share option - Stock Titan
Ernexa Therapeutics Inc. (ERNA) grants CEO 118,848 options expiring 2036 - Stock Titan
Ernexa (NASDAQ: ERNA) pays director with $4.57 stock options - Stock Titan
Ernexa Therapeutics (ERNA) grants director 5,943 stock options at $4.57 - Stock Titan
Eterna Therapeutics Inc (NASDAQ: ERNA) Share Price, ERNA Stock News, ERNA Share Price & Updates - Kalkine
Ernexa Therapeutics : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Ernexa (NASDAQ: ERNA) director’s warrant set to lapse after Phase 1 data - Stock Titan
Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference - Yahoo Finance
Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference - GlobeNewswire
Ernexa (ERNA) Earnings Reading: Reported EPS Misses Expectations at the Close; Closing Move: The Market Price Advances 3.60%Free Cash Flow Trends - vinanet.vn
Ernexa (ERNA) Quarterly Results: Reported EPS Misses Expectations in the Current Update; Post-Report: The Share Price Adds 4.68% on the DayEBITDA Analysis - vinanet.vn
Ernexa (ERNA) Quarterly Results: Reported EPS Misses Expectations in the Current Update; Post-Report: The Share Price Adds 4.68% on the DayGuidance Accuracy Score - vinanet.vn
ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know - qz.com
Ernexa Therapeutics Warrants (ERNAW) Hold at $0.05 as Price Action Remains FlatAccumulation Line - vinanet.vn
Ernexa Therapeutics (ERNA) Slips 2.2% to $4.17, Testing Key Support Amid Biotech PullbackCatalyst Driven Stocks - vinanet.vn
Ernexa Therapeutics (ERNA) Slips 2.2% to $4.17, Testing Key Support Amid Biotech PullbackProtective Put - dars.gov.et
Ernexa Therapeutics (ERNA) Slips 0.7% to $4.27, Holds Above Key Support at $4.06Regression Channel - vinanet.vn
Ernexa Therapeutics (ERNA) Slips 0.7% to $4.27, Holds Above Key Support at $4.06Double Top - dars.gov.et
Ernexa Therapeutics Warrants (ERNAW) Surge 20% to $0.06 as Speculative Interest BuildsFibonacci Extension - vinanet.vn
Ernexa appoints David Polinsky to board ahead of IND filing By Investing.com - Investing.com Nigeria
Ernexa appoints David Polinsky to board ahead of IND filing - Investing.com
Ernexa appoints David Polinsky to board ahead of IND filing By Investing.com - Investing.com UK
Ernexa Therapeutics Strengthens Board with Veteran Biotech - GlobeNewswire
Ernexa Therapeutics Inc expected to post a loss of $3.84 a shareEarnings Preview - TradingView
Ernexa Therapeutics (NASDAQ: ERNA) details $9.5M loss and cash strategy - Stock Titan
Tranche Update on Ernexa Therapeutics Inc.'s Equity Buyback Plan announced on November 25, 2024. - marketscreener.com
Price to sales forward of Ernexa Therapeutics Inc. – NASDAQ:ERNA - TradingView
Price to earnings forward of Ernexa Therapeutics Inc. – NASDAQ:ERNA - TradingView
Price to book forward of Ernexa Therapeutics Inc. – NASDAQ:ERNA - TradingView
Ernexa Therapeutics Inc. Revenue Breakdown – NASDAQ:ERNAW - TradingView
Ernexa Therapeutics Warrants (ERNAW) Hold Flat at $0.04 as Support and Resistance AlignDollar Neutral Pair - careplusvn.com
Ernexa Therapeutics Warrants (ERNAW) Hold Flat at $0.04 as Support and Resistance AlignCall Resistance - vinanet.vn
Ernexa Therapeutics (ERNA) Drops Nearly 5% as Bearish Pressure Builds Near Key SupportMarket Profile - dars.gov.et
Ernexa Therapeutics (ERNA) Drops Nearly 5% as Bearish Pressure Builds Near Key SupportNew Listing Stocks - vinanet.vn
Ernexa Therapeutics Inc. Revenue Breakdown – BOATS:ERNAW - TradingView
Ernexa Therapeutics (ERNA) Poised at Support: Is the Consolidation Nearing an End?MFI Overbought - vinanet.vn
Ernexa Therapeutics Warrants (ERNAW) Slide 21.79% as Penny-Stock Volatility IntensifiesChandelier Stop - dars.gov.et
Ernexa Therapeutics Inc. (ERNA) stock price, news, quote and history - Yahoo Finance UK
Ernexa Therapeutics Inc. (ERNA) stock price, news, quote and history - Yahoo Finance Singapore
Ernexa Therapeutics Inc. (ERNA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ernexa Therapeutics advances ERNA-101, a cell t... - Pluang
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 - GlobeNewswire
Tumors cleared in about two-thirds of animals in ERNA-101 study - Stock Titan
Ernexa Therapeutics (ERNA) Q3 2023 Earnings: Clinical-Stage Biotech Reports Wider Loss as Pipeline AdvancesDividend Cut Risk - dars.gov.et
Ernexa's Innovative Approach to Cancer Treatment - Intellectia AI
Ernexa Therapeutics Inc Stock (ERNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):